Welcome to SuperLan Chemical Co.,Ltd.
Home > Products > Cell Cycle > Aurora Kinase > MK8745

MK8745

(CAS No:885325-71-3)
MK-8745 is a potent and selective Aurora A inhibitor with IC50 of 0.6 nM, more than 450-fold selectivity for Aurora A over Aurora B.
CAS No:885325-71-3
Molecular Weight(MW):431.91
Purity:99.00%
Specification:500MG;1G;5G;10G;50G;100G
Price and large packaging, please e-mail consultation:info@SuperLan-chem.com
QC Documents
 COA  MSDS  HPLC  NMR
ChemicalInfomation
CAS No: 885325-71-3
Molecular formula(MF) C20H19ClFN5Os
Molecular Weight(MW): 431.91
Alias
Solubility
In vitro DMSO 86 mg/mL (199.11 mM)
Ethanol 1 mg/mL (2.31 mM)
Water <1 mg/mL
In vivo
Biological Activity
Description MK-8745 is a potent and selective Aurora A inhibitor with IC50 of 0.6 nM, more than 450-fold selectivity for Aurora A over Aurora B.
Targets
Aurora A [1] Aurora B [1]
0.6 nM 280 nM
In vitro

MK-8745 leads to cell cycle arrest at the G2/M phase with accumulation of tetraploid nuclei followed by cell death in non-Hodgkin lymphoma (NHL) cell lines. Treatment with MK-8745 induces p21(waf1/cip1) and CycB1, indicating cell cycle arrest and an increase in the G2/M phase cell population. Following MK-8745 treatment, Aurora-A substrates (TACC3, Eg5 and TPX2) are rapidly degraded following the reduction of phospho-Aurora-A. [1] MK8745 induces apoptotic cell death in a p53-dependent manner when tested in vitro in cell lines of multiple lineages. Exposure of p53 wild-type cells to MK8745 results in the induction of p53 phosphorylation (ser15) and an increase in p53 protein expression. p53-dependent apoptosis by MK8745 is further confirmed in HCT 116 p53(-/-) cells transfected with wild-type p53. [2]